Emerging treatments
Capivasertib
Capivasertib is an oral competitive kinase domain inhibitor that inhibits signaling through the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway. In one open-label trial, 35 people with AKT1 E17K-mutated cancers received capivasertib, including 7 women with endometrioid adenocarcinoma of the endometrium or ovary. The overall response rate was 28.6%, with one patient with endometrioid endometrial adenocarcinoma achieving a complete response. Eleven patients discontinued capivasertib due to an adverse event.[232]
Use of this content is subject to our disclaimer